found Documents: 311

Announcements & Press Releases, Group | 1 Mar 2016

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT

View Full Announcement (PDF)

Announcements & Press Releases, Group | 1 Mar 2016

Final Results for the year ended 31 December 2015

5 items

Record profit from operations at both Group and Commercial Platform levels Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015 Seven drug candidates – 19 active clinical trials – 3 Phase III

View Full Announcement (PDF)View Announcement Summary (PDF)View Chairman's Statement (PDF)View Operations Review (PDF)View Financial Statements (PDF)

Announcements & Press Releases, Group | 11 Feb 2016

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

1 item

Fourth Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

Final Results for the year ended 31 December 2015

Third Public Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia

Initiation of sulfatinib Phase III registration study in neuroendocrine tumour patients

US$105 million Shanghai land compensation agreement

Initiation of fruquintinib Phase III registration trial in non-small cell lung cancer

Second Public Filing of Registration Statement on Form F‑1 for potential Nasdaq Stock Market Listing

Chi-Med initiates sulfatinib U.S. clinical trials

Sulfatinib clinical results and fruquintinib-savolitinib combination preclinical results to be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers

Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment

Hutchison China MediTech Limited Files Registration Statement for Potential Nasdaq Stock Market Listing

Shareholders' Circular and Notice of Extraordinary General Meeting

Filing of Registration Statement on Form F-1 for potential Nasdaq Stock Market Listing

Savolitinib completes enrolment for Phase II clinical trial in Papillary Renal Cell Carcinoma

Winner of International Company of the Year 2015, AIM

Fruquintinib Phase II clinical results in colorectal cancer to be presented at the 2015 European Cancer Congress

Second proof-of-concept trial of fruquintinib achieves its primary endpoint

Termination of Research & Development Alliance Agreement with Janssen Relating to HMPL-507 Project

Interim Results for the Six Months Ended 30 June 2015

Mitsui exchanges its shares in Hutchison MediPharma for shares in Chi-Med

20-year invention patent granted on Chi-Med's best selling prescription drug

Savolitinib (AZD6094) preliminary Phase Ib clinical data in lung cancer presented at the 2015 ASCO Annual Meeting

Positive fruquintinib proof-of-concept study results trigger payments from Lilly

The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint

Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer; Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer

Final Results for the year ended 31 December 2014

Hutchison Sinopharm and AstraZeneca China signed an exclusive distribution agreement on Seroquel® in China

Initiation of fruquintinib Phase III registration study in colorectal cancer

Drug R&D Update Briefing for Analysts and Investors on 17 October 2014

Chi-Med and Merck Serono sign co-promotion agreement

Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer

HMPL-004 NATRUL-3 interim analysis result

Interim Results for the Six Months Ended 30 June 2014

Initiation of Phase I clinical trial of novel Syk Inhibitor HMPL - 523 for autoimmune diseases

Initiation of fruquintinib Phase II study in non-small cell lung cancer

Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation

Initiation of AZD6094 (HMPL-504/volitinib) Global Phase II Study in Papillary Renal Cell Carcinoma

Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting

Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture

Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting

Initiation of fruquintinib Phase II study in colorectal cancer

Final Results for the year ended 31 December 2013

Chi-Med and Sinopharm form China drug distribution and marketing joint venture

Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing

Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.

Cancer Therapy Collaboration with Lilly

Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013

Interim Results for the Six Months Ended 30 June 2013